Adulteration meeting set
This article was originally published in The Tan Sheet
FDA schedules a May 1 public meeting to discuss methods for better predicting and preventing economically motivated adulteration of regulated products. The meeting in College Park, Md., will address what industry is doing and could do to prevent EMA. FDA, the U.S. Pharmacopeia and industry stakeholders are revising analytical testing standards to effectively screen for contaminated heparin, diethylene glycol in glycerin and melamine in infant formula - recent instances of EMA (1"The Tan Sheet" Feb. 16, 2009, p. 16)
You may also be interested in...
U.S. Pharmacopeia is developing a protein testing method that cannot be "tricked" by contaminants such as melamine, unlike the existing standard for analysis
Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.
The fresh cash injection will fund Phase II studies evaluating the UK firm's 12-month treatment for diabetic macular edema.